REG - Hikma Pharmaceutical - Holding(s) in Company <Origin Href="QuoteRef">HIK.L</Origin>
RNS Number : 8763FHikma Pharmaceuticals Plc16 November 2015Notification of major interests in shares
LONDON, 16 November 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:
1
Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached
Hikma Pharmaceuticals PLC
2
Reason for the notification
An acquisition or disposal of voting rights
Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached
No
An event changing the breakdown of voting rights
No
Other (please specify): Compliance with the Transparency Directive
No
3
Full name of the person subject to the notification obligation
FMR LLC
4
Full name of shareholders
See Section 9
5
Date of the Transaction (and date on which the threshold crossed is reached differently)
13th November 2015
6
Date on which the issuer notified
16th November 2015
7
Threshold that is crossed
5%
8
Notified details
See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)
Situation previous to the triggering transaction
Resulting situation after the triggering transaction
Number of shares
Number of voting rights
Number of shares
Number of voting rights
% of voting rights
Direct
Indirect
Direct
Indirect
Direct
Indirect
Ordinary Shares (0.10 GBP)
GB00B0LCW083
9,966,682
9,966,682
10,038,352
10,038,352
5.03%
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights that may be acquired if the instrument if exercised/converted
% of voting rights
-
-
-
-
-
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument
Exercise Price
Expiration Date
Exercise/Conversion Period/Date
Number of voting rights instrument refers to
% of voting rights
Nominal
Delta
-
-
-
-
-
-
-
Total A+B+C
Number of Voting rights
% of voting rights
10,038,352
5.03
9
Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable
Custodian
Day to Day IM
Total
BANK OF NEW YORK BRUSSELS (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
6,040
BANK OF NEW YORK MELLON
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
116,750
BNP PARIBAS SEC SVCS LONDON
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
45,902
BROWN BROS HARRIMN LTD LUX (C)
FMRC-FMR CO., INC
563
BROWN BROTHERS HARRIMAN AND CO
FMRC-FMR CO., INC
68,146
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
44,975
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
55,245
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
537,558
CIBC MELLON TRUST (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
13,333
CITIBANK NA, HONG KONG BR (S)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
16,382
JP MORGAN, BOURNEMOUTH (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
9,809
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
113,142
JPMORGAN CHASE BANK
FMRC-FMR CO., INC
4,142,658
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
151,087
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
34,638
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
54,815
MELLON BANK NA (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
259,991
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
72,600
NATIONAL BANK TRUST (C)
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
14,829
NOMURA TRUST AND BANKING (C)
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
553
NORTHERN TRUST CO (C)
FMRC-FMR CO., INC
207,323
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED
2,598,333
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
36,157
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
272,510
STATE STREET BANK AND TR CO
FMRC-FMR CO., INC
312,875
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC
470,644
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY
381,494
Grand Total
10,038,352
Proxy Voting
10
Name of the proxy holder
FMR LLC
11
Number of voting rights proxy holder will acquire
71.670
12
Date on which proxy holder will acquire voting rights
13th November 2015
13
Additional Information
14
Contact name:
Peter Speirs, Company Secretary
15
Contact telephone number:
020 7399 2772
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.
This information is provided by RNSThe company news service from the London Stock ExchangeENDHOLUNRVRVAAAAAA
Recent news on Hikma Pharmaceuticals
See all newsREG - Hikma Pharmaceutical - Director/PDMR Shareholding
AnnouncementREG - Hikma Pharmaceutical - Transaction in Own Shares
AnnouncementREG - Hikma Pharmaceutical - Transaction in Own Shares
AnnouncementREG - Hikma Pharmaceutical - Transaction in Own Shares
AnnouncementREG - Hikma Pharmaceutical - Transaction in Own Shares
Announcement